<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104842</url>
  </required_header>
  <id_info>
    <org_study_id>GMMG-CONCEPT</org_study_id>
    <nct_id>NCT03104842</nct_id>
  </id_info>
  <brief_title>Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone</brief_title>
  <official_title>Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and&#xD;
      maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and&#xD;
      Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD negativity</measure>
    <time_frame>after consolidation , an average of 1 year from first dosis</time_frame>
    <description>MRD negativity (8-color flow, Euro-Flow plus Black Swan Panel)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Induction Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd), after intensification another 4 cycles of I-KRd as consolidation will be followed by IKR maintenance until PD or Toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B No-Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients &gt; 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd) (6 Cycles Induction, 2 Cycles Intensification, 4 Cycles Consolidation),to be followed by I-KR maintenance util PD or Toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Antibody Intravenous</description>
    <arm_group_label>Arm A Transplantation</arm_group_label>
    <arm_group_label>Arm B No-Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Arm A Transplantation</arm_group_label>
    <arm_group_label>Arm B No-Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Capsel</description>
    <arm_group_label>Arm A Transplantation</arm_group_label>
    <arm_group_label>Arm B No-Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Capsel</description>
    <arm_group_label>Arm A Transplantation</arm_group_label>
    <arm_group_label>Arm B No-Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have newly diagnosed, untreated, symptomatic (according to the revised&#xD;
             CRAB criteria 2014), documented myeloma and have measurable disease (serum M-protein ≥&#xD;
             1 g/dL (for IgA ≥ 0.5 g/dL) or urine M-protein ≥ 200 mg/24 hours) or in case of&#xD;
             oligosecretory myeloma: involved FLC level ≥ 10 mg/dl, provided sFLC ratio is abnormal&#xD;
             or in case of asecretory myeloma: &gt; 1 focal lesions measurable by MRI&#xD;
&#xD;
             Subjects must have high-risk myeloma defined as followed:&#xD;
&#xD;
               -  Presence of one or more of the following cytogenetic abnormalities (determined by&#xD;
                  FISH):&#xD;
&#xD;
                    -  Del(17p) in ≥ 10% of purified cells&#xD;
&#xD;
                    -  t(4;14)&#xD;
&#xD;
                    -  &gt; 3 copies +1q21&#xD;
&#xD;
               -  ISS Stage II or III (all patients)&#xD;
&#xD;
               -  FISH analysis of external laboratories other than Heidelberg is accepted, a list&#xD;
                  of laboratories will be filed in the study central.&#xD;
&#xD;
          2. Must be ≥ 18 years at the time of signing the informed consent form.&#xD;
&#xD;
          3. Must be able to adhere to the study visit schedule and other protocol requirements in&#xD;
             the investigators opinion.&#xD;
&#xD;
          4. WHO performance status 0-3 (WHO=3 is allowed only if caused by MM and not by co-morbid&#xD;
             conditions)&#xD;
&#xD;
          5. Females of childbearing potential (FCBP) (1) must agree to refrain from becoming&#xD;
             pregnant for 28 days prior to initiation of study drug, while on study drug and for 30&#xD;
             days* after discontinuation from the study drug by using 2 reliable methods of&#xD;
             contraception and must agree to regular pregnancy testing during this timeframe.&#xD;
&#xD;
               -  A female of childbearing potential is a sexually mature woman who: 1) has not&#xD;
                  undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally&#xD;
                  postmenopausal (amenorrhea following cancer therapy does not rule out&#xD;
                  childbearing potential) for at least 24 consecutive months (i.e., who has had&#xD;
                  menses at any time in the preceding 24 consecutive months) 3) has achieved&#xD;
                  menarche at some point.&#xD;
&#xD;
          6. Females must agree to abstain from breastfeeding during study participation and 30&#xD;
             days* after study drug discontinuation.&#xD;
&#xD;
          7. Males must agree to use a latex condom during any sexual contact with FCBP while&#xD;
             participating in the study and for 90 days* following discontinuation from this study,&#xD;
             even if he has undergone a successful vasectomy.&#xD;
&#xD;
          8. Males must also agree to refrain from donating semen or sperm while on treatment with&#xD;
             any study drug and for 90 days* after discontinuation from this study treatment.&#xD;
&#xD;
          9. All subjects must agree to refrain from donating blood while on study drug and for 28&#xD;
             days after discontinuation from this study treatment.&#xD;
&#xD;
         10. All subjects must agree not to share medication.&#xD;
&#xD;
         11. All participating subjects have to follow the requirements of the Lenalidomide&#xD;
             Pregnancy Prevention Plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to any of the required concomitant drugs or supportive treatments,&#xD;
             including hypersensitivity to antiviral drugs. Known history of allergy to Captisol®&#xD;
             (a cyclodextrin derivative used to solubilize Carfilzomib), mannitol, sucrose,&#xD;
             histidine (as base and hydrochloride salt) and polysorbate 80 or any of the components&#xD;
             of study therapy that are not amenable to premedication with steroids and H2 blockers&#xD;
             or would prohibit further treatment with these agents.&#xD;
&#xD;
          2. Patients with known systemic amyloidosis (except for AL amyloidosis of the skin or the&#xD;
             bone marrow)&#xD;
&#xD;
          3. Administration of systemic chemotherapy, biological, immunotherapy or any&#xD;
             investigational agent (therapeutic or diagnostic) for multiple myeloma except&#xD;
             bisphosphonate therapy. Emergency treatment with dexamethasone is allowed when the&#xD;
             cumulative dexamethasone dose is less or equal 160 mg. It is allowed to include&#xD;
             patients in the trial after 1 cycle (4 weeks) of any anti-myeloma first-line&#xD;
             treatment.&#xD;
&#xD;
          4. Any of the following laboratory abnormalities:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1,000/μL, unless related to myeloma&#xD;
&#xD;
               -  Platelet count &lt; 30,000/ μL (in case of platelets &lt; 50.000 /µl and ≥ 30.000 /µl&#xD;
                  myeloma bone marrow infiltration should be ≥ 50%)&#xD;
&#xD;
               -  Corrected serum calcium &gt; 14 mg/dL (&gt; 3.5 mmol/L); or free ionized calcium &gt; 6.5&#xD;
                  mg/dL (&gt; 1.6 mmol/L)&#xD;
&#xD;
               -  Serum GOT/AST or SGPT/ALT &gt; 3.0 x upper limit of normal (ULN) or serum total&#xD;
                  bilirubin &gt; 2.0 mg/dL if not due to hereditary abnormalities as Gilbert's disease&#xD;
                  or hereditary hemolysis (Note: if the mentioned limits for bilirubin or ASAT/ALAT&#xD;
                  are exceeded, but there is no significant hepatic dysfunction at investigator's&#xD;
                  discretion, the Tuebingen study office has to be consulted prior to inclusion)&#xD;
&#xD;
               -  Patients with severe renal impairment (eGFR &lt; 30 ml/min/1.73 m², MDRD formula or&#xD;
                  CDK-EPI or Creatinine Clearance &lt; 30 ml/min)&#xD;
&#xD;
          5. Active congestive heart failure (NYHA Class III to IV), symptomatic cardiac ischemia,&#xD;
             or conduction abnormalities uncontrolled by conventional intervention. Myocardial&#xD;
             infarction within four months prior study entry.&#xD;
&#xD;
          6. Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients&#xD;
             with hepatitis B sAg and core antibody receiving and responding to antiviral therapy&#xD;
             directed at hepatitis B: these patients are allowed).&#xD;
&#xD;
          7. Acute active, uncontrolled infection&#xD;
&#xD;
          8. Significant neuropathy (Grades 3 to 4, or Grade 2 with pain according CTC V4.03)&#xD;
&#xD;
          9. Second malignancy within the past 5 years except:&#xD;
&#xD;
               -  adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               -  carcinoma in situ of the cervix&#xD;
&#xD;
               -  prostate cancer Gleason Score ≤ 6 with stable PSA over the past 12 months&#xD;
&#xD;
               -  breast carcinoma in situ with full surgical resection&#xD;
&#xD;
               -  treated medullary or papillary thyroid cancer&#xD;
&#xD;
         10. Patients with pleural effusions requiring thoracentesis or ascites requiring&#xD;
             paracentesis within 14 days prior to study entry.&#xD;
&#xD;
         11. Major surgery within 4 weeks prior to cycle 1 day 1 (kyphoplasty is not considered&#xD;
             major surgery); subjects should have been fully recovered from any surgical related&#xD;
             toxicities.&#xD;
&#xD;
         12. Female patients who are pregnant or lactating&#xD;
&#xD;
         13. Any other clinically significant medical disease or psychiatric condition that, in the&#xD;
             Investigator's opinion, may interfere with protocol adherence or a patient's ability&#xD;
             to give informed consent.&#xD;
&#xD;
         14. Participation in any other clinical trial (with the exclusion of observational,&#xD;
             non-interventional studies))&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Weisel, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vivantes Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Benjamin Franklin Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Kliniken Bielefeld Klinikum Mitte</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Eschweiler</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Altona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie, Onkologie und GastroenterologieKliniken Maria Hilf GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Tumordiagnostik und -therapieHämatologie/Int. Onkologie</name>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8508</url>
    <description>Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial.</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytogenetic High-Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

